216 related articles for article (PubMed ID: 6208106)
21. Subsets of T lymphocyte subpopulations after human marrow transplantation defined by monoclonal antibodies and two-color fluorescence.
Farrell C; Atkinson K; Chapman G; Penny R; Biggs J
Transplant Proc; 1985 Apr; 17(2):1704-6. PubMed ID: 3885509
[No Abstract] [Full Text] [Related]
22. [Regeneration of the immune system after bone marrow transplantation].
Uher F; Puskás E; Torbágyi E; Barta A; Kormos L; Pálóczi K
Orv Hetil; 2001 Jan; 142(2):59-65. PubMed ID: 11209506
[TBL] [Abstract][Full Text] [Related]
23. [Immunological problems in organ transplantation (with reference to oncology)].
Gazzera G
G Batteriol Virol Immunol Ann Osp Maria Vittor Torino; 1970; 63(9):599-614. PubMed ID: 4932115
[No Abstract] [Full Text] [Related]
24. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
[TBL] [Abstract][Full Text] [Related]
25. Role of naturally arising regulatory T cells in hematopoietic cell transplantation.
Nguyen VH; Zeiser R; Negrin RS
Biol Blood Marrow Transplant; 2006 Oct; 12(10):995-1009. PubMed ID: 17084366
[TBL] [Abstract][Full Text] [Related]
26. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
Michallet M; Dhedin N; Michallet AS
Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
[TBL] [Abstract][Full Text] [Related]
27. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
[TBL] [Abstract][Full Text] [Related]
28. Donor double-negative Treg promote allogeneic mixed chimerism and tolerance.
He KM; Ma Y; Wang S; Min WP; Zhong R; Jevnikar A; Zhang ZX
Eur J Immunol; 2007 Dec; 37(12):3455-66. PubMed ID: 18000953
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
30. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
[TBL] [Abstract][Full Text] [Related]
31. The role of immunotherapy in bone marrow transplantation for acute myeloid leukemia.
Prentice HG; Macdonald ID; Hamon MD
Prog Clin Biol Res; 1994; 389():239-43. PubMed ID: 7700907
[No Abstract] [Full Text] [Related]
32. The problems and practice of bone marrow transplantation in man: the severe combined immunodeficiency syndrome as the ideal model.
Levey RH
Transplant Proc; 1972 Dec; 4(4):565-6. PubMed ID: 4405148
[No Abstract] [Full Text] [Related]
33. [Bone marrow regulatory factors (BMRF) and the transplanting of bone marrow: a model of morphostasis and immunity].
Pierpaoli W; Maestroni GJ
Fiziol Cheloveka; 1984; 10(2):234-41. PubMed ID: 6398233
[No Abstract] [Full Text] [Related]
34. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
[TBL] [Abstract][Full Text] [Related]
35. Organ tolerance following cadaveric liver transplantation for chronic graft-versus-host disease after allogeneic bone marrow transplantation.
Urban CH; Deutschmann A; Kerbl R; Lackner H; Schwinger W; Königsrainer A; Margreiter R
Bone Marrow Transplant; 2002 Oct; 30(8):535-7. PubMed ID: 12379895
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic bone marrow transplantation: relation between chimaerism and immunity.
Vossen J
Verh K Acad Geneeskd Belg; 1998; 60(2):111-43; discussion 143-5. PubMed ID: 9703764
[TBL] [Abstract][Full Text] [Related]
37. Xenophobia, T cells and a journey to a foreign land.
Gale RP; Butturini A
Thymus; 1990 Aug; 16(1):1-5. PubMed ID: 2219230
[No Abstract] [Full Text] [Related]
38. Simultaneous protection against allograft rejection and graft-versus-host disease after total lymphoid irradiation: role of natural killer T cells.
Liu YP; Li Z; Nador RG; Strober S
Transplantation; 2008 Feb; 85(4):607-14. PubMed ID: 18347541
[TBL] [Abstract][Full Text] [Related]
39. [Immunologic reactions in transplantation].
Vartdal F; Thorsby E
Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3167-70. PubMed ID: 10522486
[TBL] [Abstract][Full Text] [Related]
40. Marrow transplantation in the treatment of acute childhood leukemia. Historical development and current approaches.
Johnson FL
Am J Pediatr Hematol Oncol; 1981; 3(4):389-95. PubMed ID: 7036780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
